trovafloxacin + levofloxacin

Trovafloxacin + levofloxacin is a hypothetical combination of two fluoroquinolone antibiotics, each with broad-spectrum antibacterial activity. Both agents act by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, repair, and recombination. Trovafloxacin was developed as a potent fluoroquinolone but has been withdrawn from the market in many countries due to severe hepatotoxicity concerns. Levofloxacin is an FDA-approved third-generation fluoroquinolone used to treat various serious bacterial infections including respiratory tract infections, urinary tract infections, skin infections, anthrax exposure prophylaxis, and plague. The combination would theoretically provide enhanced coverage against a wide range of Gram-positive and Gram-negative bacteria; however, there are no known marketed products or clinical guidelines supporting the use of this specific combination.